{
  "schemaVersion": "portfolio-monitor-public-sample/v1",
  "sampleDate": "2026-09-05",
  "checkedDate": "2026-09-05",
  "status": "baseline-only",
  "cadence": "not-established",
  "source": {
    "name": "ClinicalTrials.gov",
    "authority": "ClinicalTrials.gov API v2",
    "publicUrl": "https://clinicaltrials.gov/"
  },
  "scope": {
    "assetCount": 5,
    "recordCount": 10,
    "assets": [
      {
        "slug": "semaglutide",
        "recordCount": 2
      },
      {
        "slug": "tirzepatide",
        "recordCount": 2
      },
      {
        "slug": "retatrutide",
        "recordCount": 2
      },
      {
        "slug": "cagrilintide",
        "recordCount": 2
      },
      {
        "slug": "survodutide",
        "recordCount": 2
      }
    ],
    "trackedFields": [
      "status",
      "phase",
      "enrollmentCount",
      "enrollmentType",
      "completionDates",
      "sponsor",
      "lastUpdatePostDate"
    ],
    "completenessClaim": "none",
    "selection": "Two selected ClinicalTrials.gov records per named asset, chosen by the declared source-date and record-ID rule."
  },
  "outcomes": {
    "baseline": 10,
    "changed": 0,
    "noChange": 0,
    "failure": 0
  },
  "records": [
    {
      "asset": "semaglutide",
      "recordId": "NCT07087795",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07087795",
      "fields": {
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": [
          "PHASE1"
        ],
        "enrollmentCount": 96,
        "enrollmentType": "ESTIMATED",
        "completionDates": {
          "primary": {
            "date": "2026-09-12",
            "type": "ESTIMATED"
          },
          "overall": {
            "date": "2026-09-25",
            "type": "ESTIMATED"
          }
        },
        "sponsor": {
          "name": "Novo Nordisk A/S",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-08-13",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "semaglutide",
      "recordId": "NCT07218354",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07218354",
      "fields": {
        "status": "RECRUITING",
        "phase": [
          "PHASE3"
        ],
        "enrollmentCount": 622,
        "enrollmentType": "ESTIMATED",
        "completionDates": {
          "primary": {
            "date": "2029-03-31",
            "type": "ESTIMATED"
          },
          "overall": {
            "date": "2030-03-30",
            "type": "ESTIMATED"
          }
        },
        "sponsor": {
          "name": "VA Office of Research and Development",
          "class": "FED"
        },
        "lastUpdatePostDate": {
          "date": "2026-08-12",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "tirzepatide",
      "recordId": "NCT07046819",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07046819",
      "fields": {
        "status": "RECRUITING",
        "phase": [
          "PHASE2"
        ],
        "enrollmentCount": 120,
        "enrollmentType": "ESTIMATED",
        "completionDates": {
          "primary": {
            "date": "2027-07-30",
            "type": "ESTIMATED"
          },
          "overall": {
            "date": "2027-07-30",
            "type": "ESTIMATED"
          }
        },
        "sponsor": {
          "name": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
          "class": "NIH"
        },
        "lastUpdatePostDate": {
          "date": "2026-08-12",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "tirzepatide",
      "recordId": "NCT07463846",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07463846",
      "fields": {
        "status": "RECRUITING",
        "phase": [
          "PHASE1",
          "PHASE2"
        ],
        "enrollmentCount": 156,
        "enrollmentType": "ESTIMATED",
        "completionDates": {
          "primary": {
            "date": "2027-04-27",
            "type": "ESTIMATED"
          },
          "overall": {
            "date": "2028-03-02",
            "type": "ESTIMATED"
          }
        },
        "sponsor": {
          "name": "Alnylam Pharmaceuticals",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-08-12",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "retatrutide",
      "recordId": "NCT05882045",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT05882045",
      "fields": {
        "status": "COMPLETED",
        "phase": [
          "PHASE3"
        ],
        "enrollmentCount": 1946,
        "enrollmentType": "ACTUAL",
        "completionDates": {
          "primary": {
            "date": "2026-04-16",
            "type": "ACTUAL"
          },
          "overall": {
            "date": "2026-05-14",
            "type": "ACTUAL"
          }
        },
        "sponsor": {
          "name": "Eli Lilly and Company",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-07-30",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "retatrutide",
      "recordId": "NCT05929079",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT05929079",
      "fields": {
        "status": "COMPLETED",
        "phase": [
          "PHASE3"
        ],
        "enrollmentCount": 1152,
        "enrollmentType": "ACTUAL",
        "completionDates": {
          "primary": {
            "date": "2026-06-16",
            "type": "ACTUAL"
          },
          "overall": {
            "date": "2026-06-16",
            "type": "ACTUAL"
          }
        },
        "sponsor": {
          "name": "Eli Lilly and Company",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-07-30",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "cagrilintide",
      "recordId": "NCT07745504",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07745504",
      "fields": {
        "status": "RECRUITING",
        "phase": [
          "PHASE3"
        ],
        "enrollmentCount": 285,
        "enrollmentType": "ESTIMATED",
        "completionDates": {
          "primary": {
            "date": "2027-05-18",
            "type": "ESTIMATED"
          },
          "overall": {
            "date": "2027-07-06",
            "type": "ESTIMATED"
          }
        },
        "sponsor": {
          "name": "Novo Nordisk A/S",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-09-04",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "cagrilintide",
      "recordId": "NCT07220759",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07220759",
      "fields": {
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": [
          "PHASE3"
        ],
        "enrollmentCount": 330,
        "enrollmentType": "ESTIMATED",
        "completionDates": {
          "primary": {
            "date": "2027-05-12",
            "type": "ESTIMATED"
          },
          "overall": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "sponsor": {
          "name": "Novo Nordisk A/S",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-09-04",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "survodutide",
      "recordId": "NCT06077864",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06077864",
      "fields": {
        "status": "COMPLETED",
        "phase": [
          "PHASE3"
        ],
        "enrollmentCount": 5531,
        "enrollmentType": "ACTUAL",
        "completionDates": {
          "primary": {
            "date": "2026-06-01",
            "type": "ACTUAL"
          },
          "overall": {
            "date": "2026-06-30",
            "type": "ACTUAL"
          }
        },
        "sponsor": {
          "name": "Boehringer Ingelheim",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-09-03",
          "type": "ACTUAL"
        }
      }
    },
    {
      "asset": "survodutide",
      "recordId": "NCT06632444",
      "outcome": "baseline",
      "checkedDate": "2026-09-05",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06632444",
      "fields": {
        "status": "RECRUITING",
        "phase": [
          "PHASE3"
        ],
        "enrollmentCount": 1800,
        "enrollmentType": "ESTIMATED",
        "completionDates": {
          "primary": {
            "date": "2031-12-27",
            "type": "ESTIMATED"
          },
          "overall": {
            "date": "2031-12-27",
            "type": "ESTIMATED"
          }
        },
        "sponsor": {
          "name": "Boehringer Ingelheim",
          "class": "INDUSTRY"
        },
        "lastUpdatePostDate": {
          "date": "2026-08-21",
          "type": "ACTUAL"
        }
      }
    }
  ]
}